Subscribe to our Newsletter

Company Overview: Developing cellular immunotherapies for severe life threatening infections. ViraCyte’s current products restore natural immunity against life threatening viruses in patients with severely weakened immune systems, such as adults and children who have recently undergone a hematopoietic stem cell transplant (HSCT). ViraCyte’s lead T cell products are in Phase 1 and Phase 2 clinical trials, with effectiveness rates of greater than 90% in patients who have failed conventional therapy. ViraCyte is planning randomized Phase II and Phase III clinical trials, which are poised to initiate patient enrollment within 6 months.
Position Summary: The Sr. Director, Clinical Operations oversees all facets …